Abstract

BackgroundThe purpose of this research was to validate the low expression of L-selectin (CD62L) in natalizumab (NTZ)-treated patients. CD62L is involved in rolling and transmigration of leukocyte cells. A correlation between CD62LCD4+ T cells low expression and progressive multifocal leukoencephalopathy (PML) development has been suggested in multiple sclerosis (MS) patients treated with NTZ.MethodsWe performed a flow cytometric analysis on peripheral blood mononuclear cells (PBMC); we collected from 23 healthy donors and 225 MS patients: untreated (n = 19) or treated with NTZ (n = 113), interferon-beta (n = 26), glatiramer acetate (n = 26), fingolimod (n = 23) and rituximab (n = 18). We have also analysed two PML/IRIS (immune reconstitution inflammatory syndrome) patients and four longitudinal samples of a NTZ-treated patients before and during the development of a clinical asymptomatic magnetic resonance imaging (MRI) lesion confirmed as PML by cerebrospinal fluid (CSF) examination. Thirty-five NTZ-treated patients were studied longitudinally with three samples taken 4 months apart.ResultsThe NTZ-treated patients showed a lower percentage of CD62L (33.68 %, n = 113) than first-line treated patients (44.24 %, n = 52, p = 0.0004). NTZ effect was already clear during the first year of treatment (34.68 %; p = 0.0184); it persisted in the following years and disappeared after drug withdrawal (44.08 %). Three percent of longitudinally analysed patients showed a percentage of CD62LCD4+ T cells under a hypothetical threshold and one patient with asymptomatic PML belongs to a group which expressed low percentage of CD62LCD4+ T cells.ConclusionsOur research confirms that NTZ has a specific effect on CD62LCD4+ T cells consisting in decreasing of the number of positive cells. The low level of CD62L found in a clinically asymptomatic PML patient strengthens its potential usefulness as a biomarker of high PML risk in NTZ-treated patients. A larger study is required to better confirm the data.Electronic supplementary materialThe online version of this article (doi:10.1186/s12974-015-0365-x) contains supplementary material, which is available to authorized users.

Highlights

  • The purpose of this research was to validate the low expression of L-selectin (CD62L) in natalizumab (NTZ)-treated patients

  • Compared to healthy donors (HD) (46.75 % ± 9.8; mean ± SD) the expression of CD62L on CD4+ T cells was significantly lower in patients treated with NTZ

  • We have analysed the expression of this molecule on CD4+ T cells from UT naïve multiple sclerosis (MS) patients or from patients treated with glatiramer acetate (GA), IFNb, FTY and RTX

Read more

Summary

Introduction

The purpose of this research was to validate the low expression of L-selectin (CD62L) in natalizumab (NTZ)-treated patients. A correlation between CD62LCD4+ T cells low expression and progressive multifocal leukoencephalopathy (PML) development has been suggested in multiple sclerosis (MS) patients treated with NTZ. NTZ showed its efficacy in the multiple sclerosis (MS) treatment by reducing the annual relapse rate in two clinical trials by 68 % [3, 4]. This monoclonal antibody is currently considered to be one of the best therapeutical options for patients with relapsing-remitting MS (RRMS) not responding to traditional therapies [5]. The most fearsome clinical complication of NTZ treatment is progressive multifocal leukoencephalopathy (PML), a John Cunningham virus (JCV) infection of the brain [6]. During therapy with NTZ, PML risk can be stratified depending on three risk factors: anti-JCV

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call